| Host: |
Rabbit |
| Applications: |
CM/ELISA/ICC/IF/IHC/IP/WB |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Phospho-PDE11A (75-125) is suitable for use in Confocal Microscopy, ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Immunoprecipitation and Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Biotin |
| Isotype: |
IgG |
| Purification: |
Affinity Purified |
| Concentration: |
0.69 µg/µl |
| Dilution Range: |
WB: 1:500ELISA: 1:10, 000IP: 1:250IHC: 1:250ICC: 1:250IF: 1:250 |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
PDE11A |
| Gene ID: |
50940 |
| Uniprot ID: |
PDE11_HUMAN |
| Immunogen Region: |
75-125 |
| Immunogen: |
Synthetic peptide taken within amino acid region 75-125 on PDE11A protein. Phosphorylated Ser 117. |
| Tissue Specificity | Isoform 1 is present in prostate, pituitary, heart and liver. It is however not present in testis nor in penis, suggesting that weak inhibition by Tadalafil (Cialis) is not relevant (at protein level). Isoform 2 may be expressed in testis. Isoform 4 is expressed in adrenal cortex. |
| Function | Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides cAMP and cGMP. Catalyzes the hydrolysis of both cAMP and cGMP to 5'-AMP and 5'-GMP, respectively. |
| Protein Name | Dual 3' -5'-Cyclic-Amp And -Gmp Phosphodiesterase 11aCamp And Cgmp Phosphodiesterase 11a |
| Database Links | Reactome: R-HSA-418457Reactome: R-HSA-418555 |
| Cellular Localisation | CytoplasmCytosol |
| Alternative Antibody Names | Anti-Dual 3' -5'-Cyclic-Amp And -Gmp Phosphodiesterase 11a antibodyAnti-Camp And Cgmp Phosphodiesterase 11a antibodyAnti-PDE11A antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
